These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Objective visual assessment of antiangiogenic treatment for wet age-related macular degeneration. Baseler HA; Gouws A; Crossland MD; Leung C; Tufail A; Rubin GS; Morland AB Optom Vis Sci; 2011 Oct; 88(10):1255-61. PubMed ID: 21705938 [TBL] [Abstract][Full Text] [Related]
44. Increased electroretinogram a-wave amplitude after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Skaat A; Solomon A; Moroz I; Hai OV; Rechtman E; Vishnevskia Dai V; Rotenstreich Y Acta Ophthalmol; 2011 May; 89(3):e269-73. PubMed ID: 20946333 [TBL] [Abstract][Full Text] [Related]
45. Rescue of retinal function by macular translocation surgery in age-related macular degeneration and other diseases with subfoveal choroidal neovascularization. Terasaki H Nagoya J Med Sci; 2001 May; 64(1-2):1-9. PubMed ID: 11486596 [TBL] [Abstract][Full Text] [Related]
46. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Ashraf M; Souka A; Adelman RA Acta Ophthalmol; 2018 Mar; 96(2):120-133. PubMed ID: 29130626 [TBL] [Abstract][Full Text] [Related]
47. Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study. Koizumi H; Yamamoto A; Ogasawara M; Maruko I; Hasegawa T; Itagaki K; Sekiryu T; Okada AA; Iida T Jpn J Ophthalmol; 2020 Jul; 64(4):338-345. PubMed ID: 32447586 [TBL] [Abstract][Full Text] [Related]
48. Evolution of oxidative stress, inflammation and neovascularization in the choroid and retina in a subretinal lipid induced age-related macular degeneration model. Kim SY; Kambhampati SP; Bhutto IA; McLeod DS; Lutty GA; Kannan RM Exp Eye Res; 2021 Feb; 203():108391. PubMed ID: 33307075 [TBL] [Abstract][Full Text] [Related]
49. Association between structural and functional treatment outcomes in neovascular age-related macular degeneration. Haji H; Gianniou C; Brynskov T; Sørensen TL; Olsen R; Krogh Nielsen M Acta Ophthalmol; 2023 Mar; 101(2):177-184. PubMed ID: 36036674 [TBL] [Abstract][Full Text] [Related]
50. Extramacular Drusen and Progression of Age-Related Macular Degeneration: Age Related Eye Disease Study 2 Report 30. Domalpally A; Xing B; Pak JW; Agrón E; Ferris FL; Clemons TE; Chew EY Ophthalmol Retina; 2023 Feb; 7(2):111-117. PubMed ID: 35940477 [TBL] [Abstract][Full Text] [Related]
51. OCT Risk Factors for Development of Late Age-Related Macular Degeneration in the Fellow Eyes of Patients Enrolled in the HARBOR Study. Nassisi M; Lei J; Abdelfattah NS; Karamat A; Balasubramanian S; Fan W; Uji A; Marion KM; Baker K; Huang X; Morgenthien E; Sadda SR Ophthalmology; 2019 Dec; 126(12):1667-1674. PubMed ID: 31281056 [TBL] [Abstract][Full Text] [Related]
52. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339 [TBL] [Abstract][Full Text] [Related]
53. Capturing the Transition From Intermediate to Neovascular AMD: Longitudinal Inner Retinal Thinning and Factors Associated With Neuronal Loss. Borrelli E; Barresi C; Lari G; Berni A; Battista M; Reibaldi M; Cascavilla ML; Bandello F Invest Ophthalmol Vis Sci; 2023 Apr; 64(4):21. PubMed ID: 37074695 [TBL] [Abstract][Full Text] [Related]
54. Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration. Kambhampati SP; Bhutto IA; Wu T; Ho K; McLeod DS; Lutty GA; Kannan RM J Control Release; 2021 Jul; 335():527-540. PubMed ID: 34058271 [TBL] [Abstract][Full Text] [Related]
55. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092 [TBL] [Abstract][Full Text] [Related]
56. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737 [TBL] [Abstract][Full Text] [Related]